Second malignancy in advanced or recurrent non‐small cell lung cancer after the advent of molecular...
Second malignancy in advanced or recurrent non‐small cell lung cancer after the advent of molecular targeted drugs and immunotherapy
About this item
Full title
Author / Creator
Masui, Yoshihiro , Shukuya, Takehito , Kataoka, Shunichi , Shiozaki, Hitomi , Kurokawa, Kana , Nakamura, Ikuko , Miyawaki, Taichi , Koinuma, Yoshika , Asao, Tetsuhiko , Kanemaru, Ryota , Shimamura, Shoko Sonobe , Mimori, Tomoyasu , Mitsuishi, Yoichiro , Tajima, Ken , Shimada, Naoko and Takahashi, Kazuhisa
Publisher
Melbourne: John Wiley & Sons Australia, Ltd
Journal title
Language
English
Formats
Publication information
Publisher
Melbourne: John Wiley & Sons Australia, Ltd
Subjects
More information
Scope and Contents
Contents
Objectives
This study aimed to investigate the characteristics of patients with recurrent or advanced non‐small cell lung cancer (NSCLC) treated with tyrosine kinase inhibitors (TKIs) or immune‐checkpoint inhibitors (ICIs) who developed secondary malignancies, as well as evaluate the impact of these secondary malignancies on the course of lung c...
Alternative Titles
Full title
Second malignancy in advanced or recurrent non‐small cell lung cancer after the advent of molecular targeted drugs and immunotherapy
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_c859515e911947f1a830ca4533f1af24
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_c859515e911947f1a830ca4533f1af24
Other Identifiers
ISSN
1759-7706,1759-7714
E-ISSN
1759-7714
DOI
10.1111/1759-7714.15457
